Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,445 total articles
Krystal Biotech, Inc. announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved VYJUVEK® (beremagene geperpavec-svdt) for treating wounds in dystrophic epidermolysis bullosa (DEB) patients from birth with COL7A1 gene mutations. This marks the first genetic medicine approval in the UK for DEB, complementing prior …
Outdoor Holding Company, owner of GunBroker.com and ammunition producer, announced a cash dividend of $0.546875 per share on its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock to be paid on June 15, 2026 to holders of record as of June 1, 2026.
Catheter Precision, Inc., a U.S.-based medical device company, announced a 200% revenue increase in Q1 2026 driven by strong growth in its electrophysiology products and the recently acquired aviation platform Flyte. The acquisition has enabled rapid scaling of Flyte's fleet and immediate revenue contribution, while the medical device segment conti…
Garrett Motion Inc. announced a successful repricing of its $635 million term loan due 2032, lowering the interest rate by 25 basis points to SOFR plus 175 basis points. The company also made an early repayment of $50 million to reduce debt, reflecting lender confidence and expected improvements in financial strength and liquidity.
Rein Therapeutics, a clinical-stage biotech focused on orphan pulmonary and fibrosis diseases, has closed an underwritten public offering raising $57.5 million. Proceeds will fully fund the ongoing Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis (IPF), support ongoing clinical and regulatory activities, and extend operational cash runway i…
Alignment Healthcare, a Medicare Advantage health services company focused on senior care, announced it will present at the prestigious Goldman Sachs Healthcare Conference, highlighting its growth and strategic initiatives in senior healthcare delivery.
Reviva Pharmaceuticals Holdings, a late-stage biopharmaceutical company focused on CNS, inflammatory, and cardiometabolic diseases, announced that its CEO, Laxminarayan Bhat, PhD, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase. The company highlighted its pipeline, including two drug candidates, brilaroxazine and…
SpyGlass Pharma announced that the AMA CPT Editorial Panel has approved a new add-on Category III CPT code for their BIM-IOL System, a drug-eluting intraocular lens implant designed to treat glaucoma and cataracts in a single surgery. This reimbursement code supports utilization tracking and future coverage, helping pave the way for product commerc…
Enlivex Ltd. has dosed the first patient in the United States as part of its global Phase 2b clinical trial evaluating Allocetra for treating moderate-to-severe age-related primary knee osteoarthritis. Following FDA IND clearance and Danish regulatory approval, the trial will assess efficacy and safety across multiple countries, targeting an unmet …
Silicon Motion Technology Corporation, a leading supplier of NAND flash controllers worldwide, announced its participation in several prestigious investor conferences throughout May and June 2026, including J.P. Morgan, B. Riley Securities, Morgan Stanley Asia AI Summit, Evercore Global TMT Conference, Citi Taiwan Tech Conference, and Bank of Ameri…
LGI Homes, Inc. has opened Cypress Trails, a premier master-planned community in Hockley near Cypress, Texas. This development features over 500 homes with a range of layouts and price points starting from the mid-$200,000s, complemented by resort-style amenities such as parks, pickleball courts, and walking trails. Positioned strategically with ea…
Enhanced Group announced a strategic multi-million dollar partnership with Rezolve Ai to utilize AI-powered technologies for its Live Enhanced consumer platform and the inaugural Enhanced Games. The collaboration will start with a mobile-first AI-enabled web experience for event attendees, featuring ticketing, athlete information, and real-time eng…
Alaunos Therapeutics announced updated preclinical results for ALN1003, their oral metabolic therapeutic candidate, demonstrating positive effects on insulin-resistance-related biomarkers, adipose tissue endocrine markers, and liver histology in diet-induced obesity mouse models. These findings support continued preclinical development for metaboli…
BIO-key International, Inc., a provider of biometric identity and access management solutions, reported a 34% revenue increase in Q1 2026 to $2.15 million and a substantially improved net loss of $165,000 versus $737,000 in the prior year period. The company expects Q2 revenues to rise 65% with profitability anticipated in the first half of 2026, d…
Core AI Holdings, Inc. reported a 58.6% year-over-year revenue increase to $55.2 million for 2025, driven by strategic focus on AI infrastructure and divestment of legacy business units. Despite short-term losses from restructuring and discontinued operations, the company is positioned for long-term growth in AI and digital platforms.
Safe Harbor Financial, a NASDAQ-listed fintech company serving the cannabis and hemp financial services markets, reported Q1 2026 revenue of approximately $2 million, marking a 2.2% year-over-year increase. The company expanded its loan program income by 55.6% due to a restructured agreement and diversified its offerings into insurance and retireme…
CervoMed reported Q1 2026 financial results and significant clinical progress, including alignment with regulatory agencies on a Phase 3 trial design for neflamapimod in dementia with Lewy bodies (DLB). New MRI and biomarker data support neflamapimod's potential as a disease-modifying therapy. Ongoing studies in frontotemporal disorders and ALS als…
Anterix (NASDAQ: ATEX) and Lynk Global have received experimental license approval from the FCC to test the integration of Lynk's satellite direct-to-device network with Anterix's licensed 900 MHz private wireless broadband spectrum. This collaboration aims to develop private, secure, resilient communication solutions for critical infrastructure se…
Inspira Technologies secured a $580,000 purchase order from NYU Langone Hospital for its FDA-cleared ART100 extracorporeal blood circulation systems after a multi-patient clinical evaluation demonstrated the system's operational value. This commercial milestone supports ongoing strategic discussions and promotes Inspira's medical technology busines…
Duos Technologies reported a strategic $200 million partnership with Hydra Host to deploy cutting-edge GPU infrastructure, supporting the company's aim to exceed $50 million in revenue for 2026. Despite a Q1 revenue decline versus the prior year due to legacy business ramp-down, Duos strengthened its balance sheet through a $65 million capital rais…
FG Nexus Inc. announced the declaration of a quarterly cash dividend of $0.50 per share on its 8.00% Cumulative Preferred Stock, Series A, payable June 15, 2026. This marks the 33rd consecutive quarterly dividend payment, reflecting the company's ongoing commitment to returning capital to its preferred shareholders while advancing its digital asset…
Armlogi Holding Corp. announced new internal financial reporting and management infrastructure initiatives including standardized cash flow reporting, higher-frequency monitoring, integrated cross-functional forecasting, and workforce allocation analysis. These measures aim to enhance management visibility, budgeting discipline, and coordination ac…
BrainsWay Ltd. has announced a strategic minority-stake investment in Hopemark Health, a mental health clinic management services organization. The initial $1.5 million investment, with potential additional milestone-based funding, aims to enhance access to advanced interventional psychiatry treatments such as Deep Transcranial Magnetic Stimulation…
Streamex Corp. announced the distribution of its second monthly yield payment for GLDY, a gold-backed, yield-bearing tokenized security, reflecting successful deployment of gold reserves into an institutional gold leasing program yielding 3.5% annually. The company emphasizes continued scaling and secondary trading venue rollouts for GLDY.
NervGen Pharma Corp. reported Q1 2026 financial results highlighting completion of a successful FDA End-of-Phase 2 meeting aligning study parameters for RESTORE, a pivotal trial for NVG-291 in chronic tetraplegia. Site activations are underway, targeting study initiation in mid-2026. The company completed its Nasdaq uplisting, strengthened its lead…
